更新于：2024-11-01

Hearing Loss, Noise-Induced

噪声性听力损失

更新于：2024-11-01

基本信息

别名

HEARING DISORDER, NOISE-INDUCED、Hearing Loss, Noise Induced、Hearing Loss, Noise-Induced

+ [32]

简介

Hearing loss due to exposure to explosive loud noise or chronic exposure to sound level greater than 85 dB. The hearing loss is often in the frequency range 4000-6000 hertz.

关联

项与噪声性听力损失相关的药物

Vatiquinone

靶点

12/15-LOX

作用机制

12/15-LOX抑制剂

在研机构

PTC Therapeutics, Inc.

原研机构

Edison Pharmaceuticals, Inc.

在研适应症

Friedreich共济失调 [+1]

非在研适应症

自闭症谱系障碍 [+12]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

Ebselen

靶点

LTB4R x Prostanoid receptor

作用机制

LTB4R拮抗剂 [+1]

在研机构

Sound Pharmaceuticals, Inc. [+1]

原研机构

Sound Pharmaceuticals, Inc.

在研适应症

梅尼埃病 [+9]

非在研适应症

化疗引起的损伤 [+5]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

FX-322

靶点-

作用机制

干细胞刺激剂

在研机构

Frequency Therapeutics, Inc.

原研机构

Frequency Therapeutics, Inc.

在研适应症

噪声性听力损失 [+1]

非在研适应症

老年性耳聋

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

项与噪声性听力损失相关的临床试验

IRCT20240430061613N1 / RecruitingN/AIIT

Creating and investigating the effect of an educational video on the attitude, awareness and performance of students of Tehran University of Medical Sciences regarding hearing loss caused by the use of personal listening devices.

开始日期2024-05-21

申办/合作机构

Tehran University of Medical Sciences

ACTRN12623001287628 / Not yet recruitingN/AIIT

Use of hearing protective devices in the clinical dental setting: a pilot study

开始日期2024-02-29

申办/合作机构

University of Melbourne

NCT06058767 / RecruitingN/AIIT

Pure-tone Audiometry Versus Otoacoustic Emissions for Preschool Hearing Screening

Children who are deaf or hard-of-hearing (D/HH) are at risk of speech and language delays, which can be mitigated through early identification and intervention. Identifying hearing loss (HL) during preschool is crucial, but the most effective hearing screening method for preschoolers remains uncertain. The purpose of this study is to learn whether, compared to the gold-standard two-stage Pure-tone audiometry (PTA) + otoacoustic emissions (OAE) screening (TS-PO), single-stage OAE (SS-O) screening alone is not inferior at identifying hearing loss when performed in a community-based preschool setting. This study holds the potential to improve early hearing loss detection and intervention among D/HH children, reducing the likelihood of speech and language delays.
A diverse group of 28,000 preschool-age children across community-based preschool centers will be recruited. The intervention involves all subjects undergoing both PTA and OAE screening, with the order determined through randomization. Children who show potential hearing issues based on screening results or teacher concerns will receive further testing to determine the final hearing outcome. Group allocation will be post-hoc, based on their screening results.
In addition to the primary objective, the study will compare other hearing screening measures and outcomes between the two methods (TS-PO and SS-O). This approach aims to reflect the real-life effectiveness of hearing screening in a diverse population. Ultimately, the study seeks to provide insights into an optimal hearing screening method that could prevent speech and language delays among D/HH children.

开始日期2023-10-01

申办/合作机构

The University of California, San Francisco

[+1]

100 项与噪声性听力损失相关的临床结果

登录后查看更多信息

100 项与噪声性听力损失相关的转化医学

登录后查看更多信息

0 项与噪声性听力损失相关的专利（医药）

登录后查看更多信息

3,288

项与噪声性听力损失相关的文献（医药）

2025-05-01·Neural Regeneration Research

Tranylcypromine upregulates Sestrin 2 expression to ameliorate NLRP3-related noise-induced hearing loss

Article

作者: Yang, Shiming ; Xu, Liangwei ; Guo, Weiwei ; Chen, Xihang ; Yuan, Shuolong ; Shi, Xi ; Lin, Chang ; Chen, Wei ; Li, Menghua ; Chen, Zhifeng

JOURNAL/nrgr/04.03/01300535-202505000-00030/figure1/v/2024-07-28T173839Z/r/image-tiff Noise-induced hearing loss is the primary non-genetic factor contributing to auditory dysfunction. However, there are currently no effective pharmacological interventions for patients with noise-induced hearing loss. Here, we present evidence suggesting that the lysine-specific demethylase 1 inhibitor–tranylcypromine is an otoprotective agent that could be used to treat noise-induced hearing loss, and elucidate its underlying regulatory mechanisms. We established a mouse model of permanent threshold shift hearing loss by exposing the mice to white broadband noise at a sound pressure level of 120 dB for 4 hours. We found that tranylcypromine treatment led to the upregulation of Sestrin2 (SESN2) and activation of the autophagy markers light chain 3B and lysosome-associated membrane glycoprotein 1 in the cochleae of mice treated with tranylcypromine. The noise exposure group treated with tranylcypromine showed significantly lower average auditory brainstem response hearing thresholds at click, 4, 8, and 16 kHz frequencies compared with the noise exposure group treated with saline. These findings indicate that tranylcypromine treatment resulted in increased SESN2, light chain 3B, and lysosome-associated membrane glycoprotein 1 expression after noise exposure, leading to a reduction in levels of 4-hydroxynonenal and cleaved caspase-3, thereby reducing noise-induced hair cell loss. Additionally, immunoblot analysis demonstrated that treatment with tranylcypromine upregulated SESN2 expression via the autophagy pathway. Tranylcypromine treatment also reduced the production of NOD-like receptor family pyrin domain-containing 3 (NLRP3) production. In conclusion, our results showed that tranylcypromine treatment ameliorated cochlear inflammation by promoting the expression of SESN2, which induced autophagy, thereby restricting NLRP3-related inflammasome signaling, alleviating cochlear hair cell loss, and protecting hearing function. These findings suggest that inhibiting lysine-specific demethylase 1 is a potential therapeutic strategy for preventing hair cell loss and noise-induced hearing loss.

2024-11-01·Neuroscience

Cortical region-specific recovery of auditory temporal processing following noise-induced hearing loss

Article

作者: Rumschlag, J.A. ; Kokash, J. ; Rumschlag, J A ; Razak, K.A. ; Razak, K A ; Kokash, J

Noise-induced hearing loss (NIHL) studies have focused on the lemniscal auditory pathway, but little is known about how NIHL impacts different cortical regions. Here we compared response recovery trajectories in the auditory and frontal cortices (AC, FC) of mice following NIHL. We recorded EEG responses from awake mice (male n = 15, female n = 14) before and following NIHL (longitudinal design) to quantify event related potentials and gap-in-noise temporal processing. Hearing loss was verified by measuring the auditory brainstem response (ABR) before and at 1-, 10-, 23-, and 45-days after noise-exposure. Resting EEG, event related potentials (ERP) and auditory steady state responses (ASSR) were recorded at the same time-points after NIHL. The inter-trial phase coherence (ITPC) of the ASSR was measured to quantify the ability of AC and FC to synchronize responses to short gaps embedded in noise. Despite the absence of click-evoked ABRs up to 90 dB SPL and up to 45-days post-exposure, ERPs from the AC and FC showed full recovery in ∼ 50 % of the mice to pre-NIHL levels in both AC and FC. The ASSR ITPC was reduced following NIHL in AC and FC in all the mice on day 1 after NIHL. The AC showed full recovery of ITPC over 45-days. Despite ERP amplitude recovery, the FC does not show recovery of ASSR ITPC. These results indicate post-NIHL plasticity with similar response amplitude recovery across AC and FC, but cortical region-specific trajectories in temporal processing recovery.

2024-10-18·Ear and hearing

Changes in Auditory Performance Following a Virtual Reality Music Concert.

Article

作者: Notaro, Dana E ; Cheng, Chin-I ; Grinn, Sarah K ; Shokar, Jatinder K

OBJECTIVESThe purpose of this study was to evaluate threshold and suprathreshold auditory risk from a newly popular platform of music concert entertainment; virtual reality (VR) headsets. Recreational noise exposure to music is the primary source of hearing hazard in young-adults, with noise doses of in-person concert venues and music festivals well in excess of the recommended daily exposure recommendation from the National Institute for Occupational Safety and Health. While research on the relationship between personal music players and noise-induced hearing loss risk is abundant, no study has yet evaluated noise-induced hearing loss risk from VR headsets, which are newest to the commercial market at this time.DESIGNThirty-one young-adult participants (18 to 25 years) with normal-hearing sensitivity (0 to 16 dB HL) experienced a VR music concert and participated in three data collection timepoints: Session A preexposure, Session A post-exposure, and Session B post-exposure. Participants underwent baseline testing for audiometry (0.25 to 20 kHz), distortion product otoacoustic emission testing (1 to 10 kHz), and Words-in-Noise testing. Participants then wore a commercially available VR headset (Meta Quest 2) and experienced a freely available online VR music concert (via the video-sharing website "YouTube"). The VR music concert duration was 90 min set to maximum volume, which yielded an average sound level equivalent of 78.7 dBA, max sound level of 88.2 dBA, and LC peak sound level of 98.6 dBA. Post-exposure testing was conducted immediately at the conclusion of the VR concert, and again within 24 hr to 1 week after the exposure. Participants also answered a questionnaire that estimated noise exposure history (National Acoustics Laboratory "Noise Calculator").RESULTSPost-exposure deficit was not observed in DPOAEs or Words-in-Noise score (p's > 0.05). However, statistically significant temporary post-exposure deficit was observed in audiometry at 4, 8, and 12.5 kHz (p's < 0.05) (mean differences: 2 to 3 dB HL). Twenty-four hours and 1-week post-exposure measurements revealed no permanent changes from baseline measurements (p's > 0.05) aside from one spurious difference at 12.5 kHz. Males tended to exhibit a significantly higher noise history score on average than females. The primary, secondary, and tertiary sources of noise hazard history in this young-adult cohort included amplified music.CONCLUSIONSThese preliminary data suggest that VR music concerts-which are likely to produce a substantially lower noise dose than in-person music concerts-may still be capable of producing at least slight, temporary threshold shifts on the order of 2 to 3 dB HL. Future research should include VR headsets in personal music player risk assessment, as the VR music concert platform is increasing rapidly in popularity among young-adults.

项与噪声性听力损失相关的新闻（医药）

2024-05-20

·BioSpace

Sound Pharmaceuticals’ IND Involving Cochlear Implantation Allowed by the FDA

SEATTLE & INNSBRUCK, Austria--(BUSINESS WIRE)-- Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI). The goal of this Phase 2 SPI-1005 (ebselen) trial is to reduce the loss of residual hearing during and after CI. Ebselen is a novel anti-inflammatory compound that mimics and induces the activity of Glutathione Peroxidase, an enzyme that is critical to hearing and balance. Ebselen has shown safety and efficacy in three different forms of acquired sensorineural hearing loss in adult patients, including loud sound exposure or acute noise induced hearing loss, Meniere’s disease, and antibiotic or aminoglycoside induced ototoxicity. The Phase 2 trial will enroll 40 adults who are CI candidates and scheduled to receive a cochlear implant. Eligible candidates will have residual low frequency hearing that is moderate to severely impaired and at risk of being lost after CI. The eligible participants will be randomized to receive 6 months of oral drug (SPI-1005 or placebo) treatment starting two days prior to CI and followed for an additional 6 months post-treatment to determine if SPI-1005 can prevent and/or treat the loss of residual hearing when compared to placebo. This marks the 6th IND involving SPI-1005, which has been tested in 13 studies enrolling over 850 participants to date. SPI-1005 is currently being tested in a pivotal Phase 3 trial involving active Meniere’s disease, where hearing loss, tinnitus, vertigo, and dizziness are common, and has received Fast Track designation by the FDA. SPI is collaborating with MED-EL, a leading medical device company that has pioneered the field of cochlear implantation over the last 40 years, especially in the area of hearing preservation. SPI and MED-EL entered into an exclusive worldwide collaborative agreement involving the use of SPI-1005 with cochlear implants. MED-EL has provided upfront, R&D, and equity support over the last 2 years. Currently, there are no FDA approved therapies for the treatment of sensorineural hearing loss, tinnitus, vertigo, or dizziness, and SPI-1005 is the only investigational new drug candidate in active Phase 3 trials for these indications or endpoints. The trials can be viewed online at , or by visiting . About Sound Pharmaceuticals (SPI) SPI is the leading biotechnology company focused on developing the first drug treatment for hearing loss and tinnitus. Sensorineural hearing loss, tinnitus, vertigo, and dizziness affect more than 50 million Americans and represent the largest neurologic disabilities throughout the industrialized world. SPI is a private company headquartered in Seattle WA and is led by co-founder and CEO Jonathan Kil, MD. Dr. Kil has led the R&D at SPI since inception and has been the Principal Investigator on multiple grants from the DoD, NIH, and the Cystic Fibrosis Foundation. About MED-EL MED-EL Medical Electronics, a leader in implantable hearing solutions, is driven by a mission to overcome hearing loss as a barrier to communication and quality of life. The Austrian-based, privately owned business was co-founded by industry pioneers Ingeborg and Erwin Hochmair, whose ground-breaking research led to the development of the world’s first micro-electronic multi-channel cochlear implant (CI), which was successfully implanted in 1977 and was the basis for what is known as the modern CI today. This laid the foundation for the successful growth of the company in 1990, when they hired their first employees. To date, MED-EL has more than 2,700 employees from around 80 nations and 30 locations worldwide. The company offers the widest range of implantable and non-implantable solutions to treat all types of hearing loss, enabling people in 136 countries enjoy the gift of hearing with the help of a MED-EL device. MED-EL’s hearing solutions include cochlear and middle ear implant systems, a combined electric acoustic stimulation hearing implant system, auditory brainstem implants as well as surgical and non-surgical bone conduction devices.

临床2期临床3期快速通道

2024-04-24

·生物谷

PNAS：新型化合物 AC102有望治疗噪声性听力损失

突发性听力损失是一种严重影响语言理解和生活质量的致残性疾病。尽管皮质类固醇治疗在实践中已有五十年的应用历史，但其有效性一直受到质疑。一项新的研究发现，在临床前模型中，单次给送新型化合物 AC102 几乎就能完全恢复噪声引起的听力损失（noise-induced hearing loss），即噪声性听力损失。相关研究结果于2024年4月1日发表在PNAS期刊上，论文标题为“A single dose of AC102 restores hearing in a guinea pig model of noise-induced hearing loss to almost prenoise levels”。突发性听力损失通常采用抗炎皮质类固醇治疗，但遗憾的是，此类疗法尚未获得监管机构的正式批准，其有效性亦缺乏确凿的科学依据。因此，寻找全新的治疗策略显得尤为重要。在本次研究中，科研人员利用噪声性听力损伤模型来评估新型化合物AC102在临床前期模型中的治疗效果。实验结果显示，受试动物在遭受噪声伤害后，仅通过一次性中耳部位施用AC102，短短14天后，其听力水平便恢复至接近损伤前的状态，而对照组在未接受AC102治疗的情况下，听力损伤依然严重。进一步的实验表明，AC102靶向导致内耳突发性听力损失的两个疑似主要原因：它能防止外毛发感觉细胞死亡和保护神经元和听觉神经之间的连接。 AudioCure Pharma公司首席运营官兼创始人Hans Rommelspacher 教授解释说，“AC102在内耳中展现的多重保护机制令人叹为观止。实验室研究显示，AC102通过提高神经元的能量生成和抑制自由基生成，从而对神经元起到了保护作用。同时，它还能够激发神经元与感觉细胞的再生潜能，重新构建丧失的神经连接。” AC102对噪声性听力损失的豚鼠模型听力的影响。图片来自PNAS, 2024, doi:10.1073/pnas.2314763121 突发性听力损失是一种严重影响语言理解和生活质量的致残性疾病。尽管皮质类固醇治疗在实践中已有五十年的应用历史，但其有效性一直受到质疑。近期，一项大型研究（HODOKORT）显示，超过 60% 的突发性听力损失患者在接受皮质类固醇治疗后并未完全康复。AudioCure Pharma公司首席执行官 Reimar Schlingensiepen 博士解释说，“HODOKORT研究清楚地指出了当前SSNHL治疗中存在的巨大缺口，因而，我们对AC102在临床前期模型中展现出的良好疗效深感鼓舞，并期待患者群体能够从这种新型治疗手段中获益。” 在顺利完成安全性与耐受性测试之后，AC102目前正在开展一项二期临床研究，以进一步评估其对突发性听力损失患者的实际疗效。（生物谷 Bioon.com）参考资料： Hans Rommelspacher et al. A single dose of AC102 restores hearing in a guinea pig model of noise-induced hearing loss to almost prenoise levels. PNAS, 2024, doi:10.1073/pnas.2314763121. Novel compound AC102 restores hearing in preclinical models of sudden hearing losshttps://medicalxpress.com/news/2024-04-compound-ac102-preclinical-sudden-loss.html

临床1期临床2期

2024-04-19

·生物谷

PNAS｜新型化合物 AC102有望治疗噪声性听力损失

一项新的研究发现，在临床前模型中，单次给送新型化合物 AC102 几乎就能完全恢复噪声引起的听力损失（noise-induced hearing loss），即噪声性听力损失。相关研究结果于2024年4月1日发表在PNAS期刊上，论文标题为“A single dose of AC102 restores hearing in a guinea pig model of noise-induced hearing loss to almost prenoise levels”。突发性听力损失通常采用抗炎皮质类固醇治疗，但遗憾的是，此类疗法尚未获得监管机构的正式批准，其有效性亦缺乏确凿的科学依据。因此，寻找全新的治疗策略显得尤为重要。在本次研究中，科研人员利用噪声性听力损伤模型来评估新型化合物AC102在临床前期模型中的治疗效果。实验结果显示，受试动物在遭受噪声伤害后，仅通过一次性中耳部位施用AC102，短短14天后，其听力水平便恢复至接近损伤前的状态，而对照组在未接受AC102治疗的情况下，听力损伤依然严重。进一步的实验表明，AC102靶向导致内耳突发性听力损失的两个疑似主要原因：它能防止外毛发感觉细胞死亡和保护神经元和听觉神经之间的连接。AudioCure Pharma公司首席运营官兼创始人Hans Rommelspacher 教授解释说，“AC102在内耳中展现的多重保护机制令人叹为观止。实验室研究显示，AC102通过提高神经元的能量生成和抑制自由基生成，从而对神经元起到了保护作用。同时，它还能够激发神经元与感觉细胞的再生潜能，重新构建丧失的神经连接。”AC102对噪声性听力损失的豚鼠模型听力的影响图片来自PNAS, 2024, doi:10.1073/pnas.2314763121突发性听力损失是一种严重影响语言理解和生活质量的致残性疾病。尽管皮质类固醇治疗在实践中已有五十年的应用历史，但其有效性一直受到质疑。近期，一项大型研究（HODOKORT）显示，超过 60% 的突发性听力损失患者在接受皮质类固醇治疗后并未完全康复。AudioCure Pharma公司首席执行官 Reimar Schlingensiepen 博士解释说，“HODOKORT研究清楚地指出了当前SSNHL治疗中存在的巨大缺口，因而，我们对AC102在临床前期模型中展现出的良好疗效深感鼓舞，并期待患者群体能够从这种新型治疗手段中获益。”在顺利完成安全性与耐受性测试之后，AC102目前正在开展一项二期临床研究，以进一步评估其对突发性听力损失患者的实际疗效。参考资料：Hans Rommelspacher et al. A single dose of AC102 restores hearing in a guinea pig model of noise-induced hearing loss to almost prenoise levels. PNAS, 2024, doi:10.1073/pnas.2314763121.Novel compound AC102 restores hearing in preclinical models of sudden hearing losshttps://medicalxpress.com/news/2024-04-compound-ac102-preclinical-sudden-loss.html本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

临床1期临床2期